Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 9—September 2020
Research

Risk-Based Estimate of Human Fungal Disease Burden, China

Ling-Hong Zhou1, Ying-Kui Jiang1, Ruo-Yu Li, Li-Ping Huang, Ching-Wan Yip, David W. Denning2, and Li-Ping Zhu2Comments to Author 
Author affiliations: Huashan Hospital, Shanghai, China; and Fudan University, Shanghai (L.-H. Zhou, Y.-K. Jiang, L.-P. Huang, C.-W. Yip, L.-P. Zhu); Peking University First Hospital, Beijing, China (R.-Y. Li); Peking University, Beijing (R.-Y. Li); National Clinical Research Center for Skin and Immune Diseases, Beijing (R.-Y. Li); Wythenshawe Hospital, Manchester, UK (D.W. Denning); University of Manchester, Manchester (D.W. Denning); Global Action Fund for Fungal Infections, Geneva, Switzerland (D.W. Denning)

Main Article

Figure 4

Prediction of HIV-related invasive fungal burden in China by 2050, based on ART and HIV-related disease incidence levels for 2012–2017. ART, antiretroviral therapy; CM, cryptococcal meningitis; PCP, pneumocystis pneumonia.

Figure 4. Prediction of HIV-related invasive fungal burden in China by 2050, based on ART and HIV-related disease incidence levels for 2012–2017. ART, antiretroviral therapy; CM, cryptococcal meningitis; PCP, pneumocystis pneumonia.

Main Article

1These authors contributed equally to this article.

2These authors contributed equally to this article.

Page created: May 26, 2020
Page updated: August 18, 2020
Page reviewed: August 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external